The Vanguard Group 13D and 13G filings for EyePoint Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-11-12 2:31 pm Unchanged | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | The Vanguard Group | 3,048,182 5.690% | 0 (Unchanged) | Filing |
2024-11-04 11:57 am Purchase | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | The Vanguard Group | 3,048,182 5.690% | 3,048,182 (New Position) | Filing |